This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aceragen 관리

관리 기준 확인 3/4

We currently do not have sufficient information about the CEO.

주요 정보

John Taylor

최고 경영자

US$444.1k

총 보상

CEO 급여 비율	17.5%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

John Taylor 의 보수는 Aceragen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$444k	US$78k	-US$23m

보상 대 시장: John's total compensation ($USD444.06K) is about average for companies of similar size in the German market ($USD438.32K).

보상과 수익: Insufficient data to compare John's compensation with company performance.

CEO

John Taylor (52 yo)

less than a year

테뉴어

US$444,062

보상

Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Taylor	President	less than a year	US$444.06k	데이터 없음
Gwen Thomas	Associate Director of Human Resources	no data	데이터 없음	데이터 없음
Christina Amendola	Director of Human Resources	no data	데이터 없음	데이터 없음
Brian Jackey	Senior Vice President of Technical Operations	no data	데이터 없음	데이터 없음
Deepa Nagpal	Global Head of Quality	no data	데이터 없음	데이터 없음
Shah Rahimian	Medical Director & Global Clinical Lead for Oncology	no data	데이터 없음	데이터 없음
Joanna Horobin	Advisor	4.2yrs	US$993.93k	데이터 없음
Louis Arcudi	Adviser	no data	US$986.13k	데이터 없음

4.2yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: V9Z's management team is considered experienced (4.2 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Taylor	President	less than a year	US$444.06k	데이터 없음
Michael Dougherty	Independent Director	4.4yrs	US$89.43k	0.26% $ 5.3k
Vincent Milano	Chair of the Board of Directors	8.8yrs	US$1.43m	0.10% $ 2.0k
Ronald Wooten	Independent Director	less than a year	US$11.88k	데이터 없음
Maxine Gowen	Independent Director	7.7yrs	US$66.24k	0% $ 0
Cristina Csimma	Independent Director	4.4yrs	US$60.12k	0% $ 0
V. Sutton	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Edward Schuchman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Atul Chopra	Member of Scientific Advisor Board	no data	데이터 없음	14.31% $ 289.2k

4.4yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: V9Z's board of directors are considered experienced (4.4 years average tenure).

This company listing is no longer active

Aceragen 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Insufficient new directors

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Senior VP & COO recently bought €50k worth of stock

Recent updates

Aceragen Files Form 15

Aceragen, Inc.(NasdaqCM:ACGN) dropped from S&P TMI Index

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought €50k worth of stock

Independent Chairman recently bought €83k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

New 90-day high: €4.48

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

President recently sold €132k worth of stock

New 90-day high: €4.20

New 90-day high: €2.96

Idera Pharmaceuticals, Inc. Announces Board Changes

Revenue in line with expectations

New 90-day high: €2.54

New 90-day high - €2.26

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령